Pharmac – Te Pātaka Whaioranga wants to hear what
people think of a funding proposal for continuous glucose
monitors (CGMs), insulin pumps, and insulin pump
consumables.
“We’ve reached provisional agreements
with suppliers to provide funded CGMs, insulin pumps, and
insulin pump consumables for people with type 1 diabetes,”
says Geraldine MacGibbon, Pharmac’s Director
Pharmaceuticals.
“Today, we’ve published a
consultation to find out what people think of these proposed
products, and how best we roll them out to the
community.”
Following the consultation and
assessment of the feedback received, a proposal to fund
CGMs, insulin pumps and insulin pump consumables will go to
Pharmac’s Board for a decision.
If funding is
approved, up to 18,000 people with type 1 diabetes would be
eligible for funded access to CGMs from 1 July
2024.
MacGibbon says it’s important to note that the
agreements Pharmac has reached with suppliers are
provisional.
“It’ll be up to Pharmac’s Board to
consider the proposal fully, including the feedback and
input we’ve had from people with type 1 diabetes, consumer
organisations and clinicians,” she says.
“This
consultation brings us a step closer to being able to fund
CGMs and the related products. We know that having these
products would be life-changing for many people and we are
making great progress in making them available.
“I
know it’s hard to wait as we go through this final stage
of the process, but we have to make sure we’re getting it
right and that the equipment we fund would provide the best
value and health outcomes.”
From 1 July 2024
we’re proposing:
- to fund a range of continuous
glucose monitors (CGMs) for everyone with type 1 diabetes,
which we expect to benefit up to 18,000 people. - to
fund one brand of insulin pump that could be paired with a
funded CGM to create an automated insulin delivery
system. - to simplify the access criteria for insulin
pumps. - to increase the limit of funded packs of
insulin pump consumables (including infusion sets, insulin
cartridges and insulin reservoirs) to 19 packs per year (an
increase from 13 currently).
From 1 October
2024 we’re proposing:
- to fund a second brand
of insulin pump that could be paired with a funded CGM to
create an automated insulin delivery system. - to fund
an additional CGM compatible with funded insulin pumps that
can be used to create an automated insulin delivery
system. - to delist the MiniMed 770G insulin pump from
the Pharmaceutical Schedule (more information
below).
Advertisement – scroll to continue reading
To find out more, including which CGMs,
insulin pumps and insulin pump consumables, are being
proposed for funding, go to Pharmac’s website:
Proposal
to fund continuous glucose monitors, insulin pumps, and
insulin pump consumables
.
MacGibbon
encourages people with an interest in the proposal to
provide feedback by emailing
consult@pharmac.govt.nz
by
4pm Friday 26
April.
© Scoop Media
Discussion about this post